1. Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research 
Michael J. Burke, Michael R. Verneris, Jennifer Le Rademacher, Wensheng He, Hisham Abdel-Azim, Allistair A. Abraham, Jeffery J. Auletta, Mouhab Ayas, Valerie I. Brown, Mitchell S. Cairo, Ka Wah Chan, Miguel A. Diaz Perez, Christopher C. Dvorak, R. Maarten Egeler, Lamis Eldjerou, Haydar Frangoul, Gregory M.T. Guilcher, Robert J. Hayashi, Ahmed Ibrahim, Kimberly A. Kasow, Wing H. Leung, Richard F. Olsson, Michael A. Pulsipher, Niketa Shah, Nirali N. Shah, Elizabeth Thiel, Julie-An Talano, Carrie L. Kitko 
Biology of Blood and Marrow Transplantation 
Volume 21, Issue 12, Pages (December 2015)
DOI: /j.bbmt
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
(A) Cumulative incidence of TRM was 13% (95% CI, 9% to 18%) at day 100, 21% (95% CI, 16% to 26%) at 1 year, and 24% (95% CI, 18% to 30%) at 3 years. (B) Probability of DFS at 3 years was 46% (95% CI, 39% to 52%).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
(A) Cumulative incidence of relapse at 3 years for patients with an isolated extramedullary relapse (central nervous system/testes) was 15% (95% CI, 5% to 28%) compared with 45% (95% CI, 32% to 58%) for patients with isolated or combined BM relapse (P < .001). (B) Probability of DFS at 3 years for patients with an isolated extramedullary relapse (central nervous system/testes) was 56% (95% CI, 39% to 72%) compared with 35% (95% CI, 23% to 47%) for patients with isolated or combined BM relapse (P = .05).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
(A) Cumulative incidence of relapse at 3 years for patients receiving HLA-matched sibling BM was 34% (95% CI, 24% to 45%), unrelated BM/PBSCs was 34% (95% CI, 23% to 46%), and unrelated UCB was 24% (95% CI, 15% to 34%) (P = .26). (B) Probability of DFS at 3 years for patients receiving HLA-matched sibling BM was 48% (95% CI, 37% to 59%), unrelated BM/PBSCs was 37% (95% CI, 25% to 49%), and unrelated UCB was 50% (95% CI, 39% to 61%) (P = .25).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions